Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jun 23;16(13):1993.
doi: 10.3390/nu16131993.

The Effect of the Lacticaseibacillus paracasei BEPC22 and Lactiplantibacillus plantarum BELP53 Combination (BN-202M) on Body Fat Percentage Loss in Overweight Individuals: A Randomized, Double-Blind, Placebo-Controlled Study

Han-Seul Kwon  1 , Seok-Jin Kim  2 , Kum-Joo Shin  2 , Sanghoon Kim  2 , Jongbok Yun  2 , Jaewoong Bae  2 , Hyun-Ji Tak  3 , Na-Rae Lee  4 , Hyeong-Jun Kim  1
Affiliations
Randomized Controlled Trial

The Effect of the Lacticaseibacillus paracasei BEPC22 and Lactiplantibacillus plantarum BELP53 Combination (BN-202M) on Body Fat Percentage Loss in Overweight Individuals: A Randomized, Double-Blind, Placebo-Controlled Study

Han-Seul Kwon et al. Nutrients. .

Abstract

BN-202M is derived from humans and consists of two strains, Lacticaseibacillus paracasei BEPC22 and Lactiplantibacillus plantarum BELP53. Body fat reduction effect and safety of BN-202M were assessed in overweight participants. A total of 150 participants were randomly assigned to the BN-202M and placebo groups at a 1:1 ratio. Dual-energy X-ray absorptiometry was used to objectively measure body fat. After 12 weeks of oral administration, the body fat percentage (-0.10 ± 1.32% vs. 0.48 ± 1.10%; p = 0.009) and body fat mass (-0.24 ± 1.19 kg vs. 0.23 ± 1.05 kg; p = 0.023) of the BN-202M group decreased significantly compared to those of the placebo group. The body weight (-0.58 kg, p = 0.004) and body mass index (BMI; -0.23, p = 0.003) was found to decrease significantly at 12 weeks in the BN-202M group, but not in the placebo group. Metabolome analysis revealed that β-alanine, 3-aminoisobutyric acid, glutamic acid, and octopamine decreased in the weight-decreased BN-202M post-intake group. In the gut microbiota analysis, Akkermansia showed a statistically significant increase in the BN-202M group post-intake compared to the placebo group. No serious adverse events were observed in either group. These results suggest that BN-202M is safe and effective for reducing body fat and weight.

Keywords: Lacticaseibacillus paracasei; Lactiplantibacillus plantarum; body fat percentage; gut microbiota; obesity; overweight; probiotics.

PubMed Disclaimer

Conflict of interest statement

Authors Han-Seul Kwon and Hyeong-Jun Kim are employed by Semyung University; Seok-Jin Kim, Kum-Joo Shin, Sanghoon Kim, Jongbok Yun and Jaewoong Bae are employed by Hecto Healthcare Co., Ltd.; Hyun-Ji Tak and Na-Rae Lee are employed by Konkuk University. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of the registered participants for the clinical trial (PP: per protocol). Adverse reactions not related to investigational product: tuberculosis (n = 1).
Figure 2
Figure 2
Comparison of gut metabolites and microbiome. (A) Partial least squares discriminant analysis (PLS-DA) score plot based on the GC-TOF-MS analysis results. (B) Heatmap representing the relative abundance of significantly discriminant metabolites (VIP > 1.0, p < 0.05) based on the PLS-DA model. (C) Box plot summarizing the significant differences at the genus level for the top and bottom 25% in the baseline and post-intake BN-202M groups.
See this image and copyright information in PMC

References

    1. Torres-Carot V., Suarez-Gonzalez A., Lobato-Foulques C. The energy balance hypothesis of obesity: Do the laws of thermodynamics explain excessive adiposity? Eur. J. Clin. Nutr. 2022;76:1374–1379. doi: 10.1038/s41430-021-01064-4. - DOI - PubMed
    1. Boutari C., Mantzoros C.S. A 2022 update on the epidemiology of obesity and a call to action: As its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217. doi: 10.1016/j.metabol.2022.155217. - DOI - PMC - PubMed
    1. Chen K.K., Wee S.L., Pang B.W.J., Lau L.K., Jabbar K.A., Seah W.T., Ng T.P. Relationship between BMI with percentage body fat and obesity in Singaporean adults—The Yishun Study. BMC Public. Health. 2021;21:1030. doi: 10.1186/s12889-021-11070-7. - DOI - PMC - PubMed
    1. Singh G.M., Danaei G., Farzadfar F., Stevens G.A., Woodward M., Wormser D., Kaptoge S., Whitlock G., Qiao Q., Lewington S., et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: A pooled analysis. PLoS ONE. 2013;8:e65174. doi: 10.1371/journal.pone.0065174. - DOI - PMC - PubMed
    1. Dancey D.R., Hanly P.J., Soong C., Lee B., Shepard J., Jr., Hoffstein V. Gender differences in sleep apnea: The role of neck circumference. Chest. 2003;123:1544–1550. doi: 10.1378/chest.123.5.1544. - DOI - PubMed

Publication types

LinkOut - more resources